SCHEMBL13699054

SCHEMBL13699054

Nc1ncc(Oc2ccccc2)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
HTT P42858 2/20 0.42
MAPT P10636 2/20 0.42
TP53 P04637 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAOA P21397 1/20 0.42
LTA4H P09960 2/20 0.41
TSHR P16473 1/20 0.41
PIK3CA P42336 1/20 0.40
PIK3C3 Q8NEB9 1/20 0.40
BCAT2 O15382 1/20 0.39
MAOB P27338 1/20 0.38
ALDH1A1 P00352 2/20 0.38
NOS1 P29475 1/20 0.38
MLYCD O95822 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210658 0.82 LMNA (0.49) HTTSMN1; SMN2LTA4HALDH1A1TDP1
SCHEMBL2655449 0.81 TEAD4 (0.47) NPC1RAB9AHTTMAPTSMN1; SMN2
SCHEMBL3772542 0.81 GAA (0.50) NPC1RAB9AHTTMAPTSMN1; SMN2
SCHEMBL2667405 0.80 CYP1A2 (0.46) L3MBTL1
SCHEMBL21384250 0.80 MAP4K4 (0.43) MAPTMAOBALDH1A1MEN1KMT2A
SCHEMBL10329783 0.80 ALDH1A1 (0.50) NPC1RAB9AHTTMAPTALDH1A1
SCHEMBL184691 0.78 ALDH1A1 (0.47) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL184686 0.78 CYP19A1 (0.44) NPC1RAB9AMAPTSMN1; SMN2MAOB
SCHEMBL31510825 0.77 KDM4E (0.42) NPC1RAB9AMAPTLTA4HPIK3CA
SCHEMBL2667220 0.76 MAP4K4 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4662211-A1 G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) DEGRADATION COMPOUNDS AND USE THEREOF Nanjing Huanbo Biotechnology Co., Ltd. (CN) 2025-12-17 EP disclosed
WO-2024165075-A1 G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) DEGRADATION COMPOUNDS AND USE THEREOF NANJING HUANBO BIOTECHNOLOGY CO., LTD. (CN) 2024-08-15 WO disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R NPC1 2338/4885RAB9A 2492/4885HTT 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.